{
    "2019-12-05": [
        [
            {
                "time": "2018-11-02",
                "original_text": "Novartis (NVS) Gains But Lags Market: What You Should Know",
                "features": {
                    "keywords": [
                        "Novartis",
                        "gains",
                        "lags market"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2019-06-15",
                "original_text": "Astellas-Audentes Deal Likely to Ignite More Acquisitions",
                "features": {
                    "keywords": [
                        "Astellas",
                        "Audentes",
                        "acquisitions"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2020-03-10",
                "original_text": "U.S. FDA approves generic versions of Novartis blockbuster MS treatment",
                "features": {
                    "keywords": [
                        "FDA",
                        "generic",
                        "Novartis",
                        "MS treatment"
                    ],
                    "sentiment_score": -0.4,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2019-12-05",
                "original_text": "Companies Are Merging Like Mad. That Might Signal a Looming Economic Slowdown.",
                "features": {
                    "keywords": [
                        "merging",
                        "economic slowdown"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "economy"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2020-02-20",
                "original_text": "UPDATE 1-Novartis R&D boss says doesn't see big opportunity in oral SMA therapy",
                "features": {
                    "keywords": [
                        "Novartis",
                        "R&D",
                        "SMA therapy"
                    ],
                    "sentiment_score": -0.3,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2020-07-15",
                "original_text": "The Daily Biotech Pulse: Aurinia Rips Higher On Positive Readout, Sesen Bio On Track For Vicinium BLA Submission",
                "features": {
                    "keywords": [
                        "Aurinia",
                        "positive readout",
                        "Sesen Bio",
                        "BLA submission"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-08-10",
                "original_text": "Is Novartis AG (NVS) A Good Stock To Buy?",
                "features": {
                    "keywords": [
                        "Novartis",
                        "good stock"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}